The FDA has approved Alyftrek (Vertex), an oral fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators vanzacaftor, tezacaftor, and deutivacaftor, for once-daily treatment of cystic fibrosis (CF) in patients ≥6 years old who have at least one F508del mutation or another responsive mutation in the CFTR gene. This is the first approval for vanzacaftor and for deutivacaftor, a deuterated form of ivacaftor. Trikafta, a twice-daily oral fixed-dose combination of elexacaftor, tezacaftor, and ivacaftor, is FDA-approved for the same indication in patients ≥2 years old.
- Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain
- Drugs for Dry Eye Disease
- Tapinarof Cream (Vtama) for Atopic Dermatitis
- A Renal Indication for Semaglutide (Ozempic)
- Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)
- Olezarsen (Tryngolza) for Familial Chylomicronemia Syndrome (online only)
- Vaccination Recommendations for Updated 2024-2025 COVID-19 Vaccines (online only)
ISSUE
The FDA has approved Azmiro (Azurity), the first injectable formulation of testosterone cypionate to become available in single-dose vials and prefilled syringes for treatment of males with conditions associated with a deficiency or absence of endogenous testosterone. Injectable testosterone cypionate has been available in multidose vials (Depo-Testosterone, and generics) for many years. Testosterone enanthate (Xyosted) is available in prefilled autoinjectors for use in adult men.1 No testosterone products are approved for treatment of low testosterone levels due solely to aging. All testosterone products are classified as schedule III controlled substances.
THE NEW PRODUCT — Testosterone cypionate can crystallize in solution when it is stored at lower-than-recommended temperatures (less than 20-25°C; 68-77°F). …